Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer
Menés respectivement sur 878 et 720 patients atteints d'un cancer du poumon non à petites cellules de stade avancé ou métastatique, ces deux essais multicentriques internationaux de phase III évaluent l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité du dacomitinib après des traitements comprenant jusqu'à 3 lignes de chimiothérapie et un inhibiteur d'EGFR
Since 2005, erlotinib has been indicated for unselected patients with non-small-cell lung cancer as second-line or third-line treatment, after findings from the BR.21 trial showed that erlotinib could increase overall survival by 2 months, irrespective of histological subtype, compared with placebo. Importantly, this activity could not be shown for gefitinib in an identical context. Afatinib, an irreversible tyrosine kinase inhibitor similar to dacomitinib that inhibits EGFR and HER2/4, also did ...
The Lancet Oncology , commentaire, 2013